Provided by Tiger Fintech (Singapore) Pte. Ltd.

Applied Genetic

0.3936
0.0000
Volume:- -
Turnover:- -
Market Cap:26.62M
PE:-0.28
High:0.3936
Open:0.3936
Low:0.3936
Close:0.3936
52wk High:0.3936
52wk Low:0.3936
Shares:67.63M
Float Shares:28.74M
Volume Ratio:0.39
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3893
EPS(LYR):-1.5310
ROE:-161.14%
ROA:-50.00%
PB:1.51
PE(LYR):-0.26

Loading ...

Company Profile

Company Name:
Applied Genetic
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.